SCHEMBL7658982

SCHEMBL7658982

COc1ccc(C(=O)Nc2ccc(C=Cc3ccc(NC(=O)c4ccc(S(C)(=O)=O)cc4)cc3S(=O)(=O)O)c(S(=O)(=O)O)c2)cc1S(=O)(=O)N1CCOCC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.64
MAPK1 P28482 4/20 0.64
ALDH1A1 P00352 4/20 0.64
SMN1; SMN2 Q16637 4/20 0.64
KDM4E B2RXH2 1/20 0.64
GAA P10253 1/20 0.64
KMT2A Q03164 8/20 0.61
MEN1 O00255 6/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
HSD17B10 Q99714 2/20 0.61
TSHR P16473 1/20 0.61
CYP2D6 P10635 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
MAPT P10636 2/20 0.57
USP2 O75604 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
HTT P42858 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7658968 1.00 LMNA (0.64) LMNAMAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL7666544 0.94 KMT2A (0.68) LMNAMAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL7666465 0.94 KMT2A (0.68) LMNAMAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL7661240 0.94 LMNA (0.57) LMNAMAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL7661224 0.94 LMNA (0.57) LMNAMAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL7665092 0.89 LMNA (0.67) LMNAMAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL7659528 0.88 ALDH1A1 (0.62) LMNAMAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL7659519 0.88 ALDH1A1 (0.62) LMNAMAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL7657503 0.86 RAB9A (0.66) LMNAMAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL7657417 0.86 RAB9A (0.66) LMNAMAPK1ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020111369-A1 Aryl sulfonic acids and derivatives as FSH antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-08-15 US claimed
WO-2000058277-A1 ARYL SULFONIC ACIDS AND DERIVATIVES AS FSH ANTAGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-10-05 WO claimed
US-20020111369-A1 Aryl sulfonic acids and derivatives as FSH antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-08-15 US disclosed
US-6355633-B1 CONTRACEPTIVES AMERICAN HOME PRODUCTS CORPORATION 2002-03-12 US disclosed
WO-2000058277-A1 ARYL SULFONIC ACIDS AND DERIVATIVES AS FSH ANTAGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111369-A1 Aryl sulfonic acids and derivatives as FSH antagonists FSHR, GNRHR, LHCGR LMNA 3330/4885MAPK1 1934/4885ALDH1A1 3990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.